News & Events

Gauging Change in Europe’s Sterile Manufacturing Market

Colin MacKay, CEO of Symbiosis Pharmaceutical Services discusses ‘Gauging Change in Europe’s Sterile Manufacturing Market’ in this guest blog as featured on

The past six months has seen some major changes to the sterile manufacturing landscape in Europe. There have been a number of exits and acquisitions that have no doubt grabbed headlines, but has anything really changed?

At an industry level, the demand for sterile injectable manufacturing capability is evident. Industry publications regularly publish indicators of growth in the market. There are many factors driving this demand, including shifting trends towards the development of oncology therapies and the increasing number of large-molecule drugs in development, which require an injectable route of administration. Additional data generated by absolute bioavailability studies to support regulatory submissions where a proven relationship exists between the pharmacodynamics and the pharmacokinetics at therapeutic dose further drive this growth.

Read the full blog here via

Get In Touch.

By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.